Three phase II trials (one as a component of the first-line treatment and two performed in recurrence), alone or in combination with conventional cytotoxic therapy, have evidenced null or only modest impact of cetuximab in the management of EOC [44–46]
Matuzumab
ErbB1
One phase II study conducted in platinum-resistant, EGFR (+) population, concluded that matuzumab was well-tolerated, but lacked significant clinical activity [47]
Pertuzumab
Her2/neu
One phase II trial involving advanced, refractory EOC patients has been conducted using this agent. Like matuzumab, pertuzumab was associated with a poor response rate (approximately 4%) [48]
